bit.bio partners with April Six on its mission to unlock the “operating system of life”
Following a year of growth which saw it secure $41.5million backing from major Silicon Valley and life sciences investors, award-winning UK biotech company bit.bio has hired science, technology and mobility specialists April Six to deliver a global public relations and public affairs programme during 2021.
Founded as a spinout from Cambridge University by Dr. Mark Kotter and Florian Schuster, bit.bio’s aim is to unlock the “operating system of life” by developing a comprehensive understanding of the genetic factors governing human cell behaviour. This will allow bit.bio to pioneer a new generation of cell therapies through the precise reprogramming of stem cells, revolutionising the treatment of cancer, neurodegenerative disorders and autoimmune diseases and accelerating drug development for a range of other conditions.
April Six, which worked with the company on two funding and partnerships announcements during 2020, has been appointed as bit.bio’s first retained communications partner without a pitch. With a remit encompassing content creation, stakeholder engagement and UK, US and DACH media relations, April Six has been tasked with building awareness of the revolutionary benefits scalable cell therapy can deliver, and regulatory challenges it needs to overcome.
bit.bio founder and CEO Dr. Mark Kotter, said, “bit.bio’s mission is to apply the principles of data science to biology to code cells for the wellbeing of humanity. The work we do is exceptionally complex, but in April Six we believe we have the ideal partner to expertly communicate our ethos, products and breakthroughs to a wide range of stakeholders.”
Jim Sutton, EMEA Managing Director for PR and communications at April Six, said, “Not only does bit.bio operate at the bleeding edge of science, but its technology will have a huge positive impact for the whole world. There’s no better example of a brand shaping the future, and everyone at April Six is hugely excited about expanding our relationship with the bit.bio team in 2021 and beyond.”